SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
A demonstrator hold a sign demanding lower drug prices during a protest in Manhattan, New York, on August 16, 2023.
(Photo: Erik McGregor/LightRocket via Getty Images)
The Biden Administration Is Pulling Drug Prices Down Out of the Stratosphere
The president’s Inflation Reduction Act contained several provisions affecting drug prices, including three that began to take effect in 2023.
Apr 03, 2024
Prices for prescription drugs in America average almost three times as much as in other major nations around the world. Even more, the companies that set those prices are doing everything they can to make sure they stay in the stratosphere: They’ve filed suit to overturn an upcoming reform, having Medicare negotiate the prices of some of the costliest and most commonly used drugs.
The makers don’t think they need to explain themselves, either. If they hadn’t been threatened with subpoenas, their CEOs would never have showed up to waffle their way through a Senate hearing on drug pricing earlier this year.
Lastly, the companies argue that critics of high prices should instead be praising the industry for all the research it carries out to make the drugs available in the first place—failing to mention, of course, the critical role that government funding regularly plays in the development of new drugs.
If you wonder how patients could be harmed by lower drug prices, feel free to ask the Pharmaceutical Research and Manufacturers of America.
A big contributor to insane drug prices is the billions spent on those incessant drug commercials. Hour after hour, eyes glazing over, TV watchers are bombarded with happy-time ads for Rinvoq, Skyrizi, Dupixent, Sanofi, Jardiance, on and on and then some.
Thank heaven for mute buttons; more to the point, thank heaven that the Biden administration is leading the way to somewhat less insanity.
The president’s Inflation Reduction Act contained several provisions affecting drug prices, including three that began to take effect in 2023. The bill capped the price of insulin at $35 a month, made some vaccines free, and required drug companies that raised prices faster than the rate of inflation to pay rebates to Medicare.
Here’s President Joe Biden taking a victory lap during his State of the Union address: “That’s not just saving seniors money, it’s saving taxpayers money. We cut the federal deficit by $160 billion because Medicare will no longer have to pay those exorbitant prices…”
Other cost-saving provisions are coming as well. Starting in 2025, out-of-pocket prescription drug costs for retirees covered under Medicare Part D will be capped at $2,000. Annual limits after 2025 will be adjusted based on inflation rates.
Medicare-negotiated drug prices, mentioned earlier, have an effective date of 2026 (unless, of course, they get derailed by Big Pharma). Negotiations between Medicare and the makers are already underway for the first 10 covered drugs; all by themselves, those 10 accounted for over $3.4 billion in out-of-pocket costs in 2022.
Drug prices could fall even more sharply under the terms of the proposed 2025 budget for the Department of Health and Human Services. Instead of Medicare-negotiated prices for 10 drugs, the number would rise to 50 per year.
Presidents also have the power to make things happen without congressional legislation, and a Biden executive order could result in allowing states to import lower-cost drugs in bulk from Canada. The Food and Drug Administration approved Florida’s request early this year, and other states are hoping to follow. (Full disclosure: Florida’s Republican Gov. Ron DeSantis and former President Donald Trump also pushed for FDA’s approval.)
Drug companies reflexively oppose lower drug prices, so of course they reflexively oppose imports from Canada. A statement from their trade association said they were “considering all options for preventing this policy from harming patients.”
If you wonder how patients could be harmed by lower drug prices, feel free to ask the Pharmaceutical Research and Manufacturers of America. Another question too: Ask if they could please, please, please cut down on those commercials (or better yet, just end them).
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Gerald Scorse
Gerald Scorse helped pass the bill requiring basis reporting on stock market capital gains. He writes articles on taxes.
Prices for prescription drugs in America average almost three times as much as in other major nations around the world. Even more, the companies that set those prices are doing everything they can to make sure they stay in the stratosphere: They’ve filed suit to overturn an upcoming reform, having Medicare negotiate the prices of some of the costliest and most commonly used drugs.
The makers don’t think they need to explain themselves, either. If they hadn’t been threatened with subpoenas, their CEOs would never have showed up to waffle their way through a Senate hearing on drug pricing earlier this year.
Lastly, the companies argue that critics of high prices should instead be praising the industry for all the research it carries out to make the drugs available in the first place—failing to mention, of course, the critical role that government funding regularly plays in the development of new drugs.
If you wonder how patients could be harmed by lower drug prices, feel free to ask the Pharmaceutical Research and Manufacturers of America.
A big contributor to insane drug prices is the billions spent on those incessant drug commercials. Hour after hour, eyes glazing over, TV watchers are bombarded with happy-time ads for Rinvoq, Skyrizi, Dupixent, Sanofi, Jardiance, on and on and then some.
Thank heaven for mute buttons; more to the point, thank heaven that the Biden administration is leading the way to somewhat less insanity.
The president’s Inflation Reduction Act contained several provisions affecting drug prices, including three that began to take effect in 2023. The bill capped the price of insulin at $35 a month, made some vaccines free, and required drug companies that raised prices faster than the rate of inflation to pay rebates to Medicare.
Here’s President Joe Biden taking a victory lap during his State of the Union address: “That’s not just saving seniors money, it’s saving taxpayers money. We cut the federal deficit by $160 billion because Medicare will no longer have to pay those exorbitant prices…”
Other cost-saving provisions are coming as well. Starting in 2025, out-of-pocket prescription drug costs for retirees covered under Medicare Part D will be capped at $2,000. Annual limits after 2025 will be adjusted based on inflation rates.
Medicare-negotiated drug prices, mentioned earlier, have an effective date of 2026 (unless, of course, they get derailed by Big Pharma). Negotiations between Medicare and the makers are already underway for the first 10 covered drugs; all by themselves, those 10 accounted for over $3.4 billion in out-of-pocket costs in 2022.
Drug prices could fall even more sharply under the terms of the proposed 2025 budget for the Department of Health and Human Services. Instead of Medicare-negotiated prices for 10 drugs, the number would rise to 50 per year.
Presidents also have the power to make things happen without congressional legislation, and a Biden executive order could result in allowing states to import lower-cost drugs in bulk from Canada. The Food and Drug Administration approved Florida’s request early this year, and other states are hoping to follow. (Full disclosure: Florida’s Republican Gov. Ron DeSantis and former President Donald Trump also pushed for FDA’s approval.)
Drug companies reflexively oppose lower drug prices, so of course they reflexively oppose imports from Canada. A statement from their trade association said they were “considering all options for preventing this policy from harming patients.”
If you wonder how patients could be harmed by lower drug prices, feel free to ask the Pharmaceutical Research and Manufacturers of America. Another question too: Ask if they could please, please, please cut down on those commercials (or better yet, just end them).
From Your Site Articles
- 'Shameless Greed': Pharma Giant Merck Sues to Kill Medicare Drug Price Negotiations ›
- 'Appalling': Biden Administration Declines to Force Big Pharma to Cut Price of Prostate Cancer Drug ›
- Seniors Rejoice as President Biden Makes Lower Drug Prices for Older Americans the Law of the Land ›
- Critics Say Biden Plan to Cut Drug Costs Too Friendly to Big Pharma ›
- Federal Judge Tosses Big Pharma Lawsuit Against Medicare Drug Price Negotiations ›
- 'Stakes Are Huge': Medicare Makes Opening Bids in Price Negotiations With Big Pharma ›
- Harris' Cap on Drug Costs Would Save Americans Billions of Dollars | Common Dreams ›
Gerald Scorse
Gerald Scorse helped pass the bill requiring basis reporting on stock market capital gains. He writes articles on taxes.
Prices for prescription drugs in America average almost three times as much as in other major nations around the world. Even more, the companies that set those prices are doing everything they can to make sure they stay in the stratosphere: They’ve filed suit to overturn an upcoming reform, having Medicare negotiate the prices of some of the costliest and most commonly used drugs.
The makers don’t think they need to explain themselves, either. If they hadn’t been threatened with subpoenas, their CEOs would never have showed up to waffle their way through a Senate hearing on drug pricing earlier this year.
Lastly, the companies argue that critics of high prices should instead be praising the industry for all the research it carries out to make the drugs available in the first place—failing to mention, of course, the critical role that government funding regularly plays in the development of new drugs.
If you wonder how patients could be harmed by lower drug prices, feel free to ask the Pharmaceutical Research and Manufacturers of America.
A big contributor to insane drug prices is the billions spent on those incessant drug commercials. Hour after hour, eyes glazing over, TV watchers are bombarded with happy-time ads for Rinvoq, Skyrizi, Dupixent, Sanofi, Jardiance, on and on and then some.
Thank heaven for mute buttons; more to the point, thank heaven that the Biden administration is leading the way to somewhat less insanity.
The president’s Inflation Reduction Act contained several provisions affecting drug prices, including three that began to take effect in 2023. The bill capped the price of insulin at $35 a month, made some vaccines free, and required drug companies that raised prices faster than the rate of inflation to pay rebates to Medicare.
Here’s President Joe Biden taking a victory lap during his State of the Union address: “That’s not just saving seniors money, it’s saving taxpayers money. We cut the federal deficit by $160 billion because Medicare will no longer have to pay those exorbitant prices…”
Other cost-saving provisions are coming as well. Starting in 2025, out-of-pocket prescription drug costs for retirees covered under Medicare Part D will be capped at $2,000. Annual limits after 2025 will be adjusted based on inflation rates.
Medicare-negotiated drug prices, mentioned earlier, have an effective date of 2026 (unless, of course, they get derailed by Big Pharma). Negotiations between Medicare and the makers are already underway for the first 10 covered drugs; all by themselves, those 10 accounted for over $3.4 billion in out-of-pocket costs in 2022.
Drug prices could fall even more sharply under the terms of the proposed 2025 budget for the Department of Health and Human Services. Instead of Medicare-negotiated prices for 10 drugs, the number would rise to 50 per year.
Presidents also have the power to make things happen without congressional legislation, and a Biden executive order could result in allowing states to import lower-cost drugs in bulk from Canada. The Food and Drug Administration approved Florida’s request early this year, and other states are hoping to follow. (Full disclosure: Florida’s Republican Gov. Ron DeSantis and former President Donald Trump also pushed for FDA’s approval.)
Drug companies reflexively oppose lower drug prices, so of course they reflexively oppose imports from Canada. A statement from their trade association said they were “considering all options for preventing this policy from harming patients.”
If you wonder how patients could be harmed by lower drug prices, feel free to ask the Pharmaceutical Research and Manufacturers of America. Another question too: Ask if they could please, please, please cut down on those commercials (or better yet, just end them).
From Your Site Articles
- 'Shameless Greed': Pharma Giant Merck Sues to Kill Medicare Drug Price Negotiations ›
- 'Appalling': Biden Administration Declines to Force Big Pharma to Cut Price of Prostate Cancer Drug ›
- Seniors Rejoice as President Biden Makes Lower Drug Prices for Older Americans the Law of the Land ›
- Critics Say Biden Plan to Cut Drug Costs Too Friendly to Big Pharma ›
- Federal Judge Tosses Big Pharma Lawsuit Against Medicare Drug Price Negotiations ›
- 'Stakes Are Huge': Medicare Makes Opening Bids in Price Negotiations With Big Pharma ›
- Harris' Cap on Drug Costs Would Save Americans Billions of Dollars | Common Dreams ›
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.